---
document_datetime: 2025-11-25 09:34:23
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/accofil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: accofil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4108926
conversion_datetime: 2025-12-30 20:44:28.310692
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Accofil

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 21/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000306984                     | variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                |            |     |                 |                                                                                                                                                                                                                                                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000294879 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted | 03/09/2025 | N/A |                 |                                                                                                                                                                                                                                                   |
| Variation type II / EMA/VR/0000263401 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.3 Including batch control/testing for a biological/immunological product and any of                                                                                                                                                                                                                                 | 12/06/2025 |     | Annex II and PL | The Annex II has been updated as follows: Accord Healthcare Single Member S.A., 64th Km National Road Athens Lamia, Schimatari, 32009, Greece has been included as a new manufacturer responsible for batch release. The Package leaflet has been |

<div style=\"page-break-after: always\"></div>

|                                       | the test methods performed at that site is a biological / immunological / immunochemical method - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |             | updated accordingly.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------|
| Variation type IB / EMA/VR/0000247287 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (IB) - To update section 4.8 of the SmPC and section 4 of the Package Leaflet to add \"Extramedullary hematopoiesis\" as an adverse reaction with a frequency of \"rare\", following approval of the same changes in the reference product. Furthermore, the Marketing Authorisation Holder has taken the opportunity to introduce editorial changes to the Product Information in order to align with the reference product and correct typographical errors in the local texts for DA, ET, EL, ES, IT, PT, and RO. | 15/05/2025 |     | SmPC and PL |                        |
| Variation type IB / EMA/VR/0000256495 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/04/2025 | N/A |             |                        |

<div style=\"page-break-after: always\"></div>

| B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------|